Ginkgo Bioworks Holdings, Inc.(DNA)Earnings Date, History & Expected Move
Next report date, beat rate and options-implied move
DNA has no upcoming report date in the calendar yet. It last reported on Nov 5, 2026; companies usually report every three months.
EPS: Actual vs Estimate
Reported EPS against the consensus estimate, last 12 quarters.
Green beat or met, red missed, amber sources differ.
Stock Reaction After Earnings
Close-to-close move in the first session that reflected each report.
Dashed lines mark the average actual move (±13.6%).
Did the stock rise after good news?
The next-day move after each of its last 7 EPS beats and 4 misses.
In plain words: it beat expectations 7 times, but the stock still fell 4 of those 7 times.
- Nov '26Beat▲ +13.4%
- May '26Missed▼ -13.5%
- Feb '26Beat▼ -30.5%
- Nov '25Missed▼ -20.8%
- Aug '25Beat▼ -8.7%
- May '25Beat▲ +14.7%
- Feb '25Beat▼ -11.5%
- Nov '24Beat▲ +2.5%
- Aug '24Missed▼ -5.6%
- May '24Beat▼ -17.3%
- Feb '24Missed▼ -15.1%
Clear beats and misses with a known reaction only. What counts as a beat
Why did DNA fall after beating earnings?
4 of DNA's last 11 reactions went against the EPS result. What stands out in each:
DNA beat EPS estimates in 7 quarters, and the stock still closed lower the next day 4 times. In 2 of the 4 where we have price data, the stock had already run up before the report.
- Feb 26, 2026EPS beat +30.6%stock -30.5% next day
- It opened 17.5% lower as soon as trading resumed.
- Aug 7, 2025EPS beat +29.9%stock -8.7% next day
- It had risen 24.7% in the 20 trading sessions before the report, so good news may already have been priced in.
- It opened 4.4% higher, but sellers took over and it closed -8.7%.
- Feb 25, 2025EPS beat +6.9%stock -11.5% next day
- It opened 14.3% lower as soon as trading resumed.
- May 9, 2024EPS beat +10.3%stock -17.3% next day
- It had risen 6.9% in the final week before the report, so good news may already have been priced in.
- It opened 13.4% lower as soon as trading resumed.
Patterns in estimates and prices, not confirmed causes: how we read them.
Was DNA's earnings move already priced in?
DNA's move in the month before each of its last 12 reports, against what it did after.
How the run-up is measured (a move of 5% or more counts as large).
Before vs after each report
Grey: the month before each of the last 12 reports. Green or red: the day after.
Past reports only. How the run-up is measured
Does DNA hold its opening gap after earnings?
DNA's opening move after each report and where it closed that day.
In 12 reports DNA opened at least 1% away from the previous close. It gave back half or more of that gap by the close 3 of 12 times (25%), and fully reversed 2 times. Gaps up faded 3 of 5; gaps down recovered 0 of 7.
- Nov 5, 2026HeldOpened +2.0%, closed +13.4%
- Aug 5, 2026HeldOpened -2.6%, closed -9.3%
- May 7, 2026HeldOpened -16.2%, closed -13.5%
- Feb 26, 2026HeldOpened -17.5%, closed -30.5%
- Nov 6, 2025HeldOpened -8.9%, closed -20.8%
- Aug 7, 2025ReversedOpened +4.4%, closed -8.7%
- May 6, 2025HeldOpened +5.9%, closed +14.7%
- Feb 25, 2025HeldOpened -14.3%, closed -11.5%
What the history says
- It fell after 4 of its 7 EPS beats (57%): beating estimates has not been enough on its own.
DNA earnings history
Last 12 reported quarters with the stock's reaction.
Swipe sideways to see every column →
| Report date | Time | EPS est. | EPS actual | Surprise | Revenue surprise | 1-day move | 3-day move |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | After close | -$0.54 | -$0.48 | +11.1% | +27.2% | +13.35% | — |
| Aug 5, 2026 | After close | -$0.70 | -$0.73 | sources differ | — | -9.29% | -18.36% |
| May 7, 2026 | After close | -$1.34 | -$1.39 | -3.7% | — | -13.47% | -19.19% |
| Feb 26, 2026 | After close | -$1.11 | -$0.77 | +30.6% | — | -30.48% | -31.00% |
| Nov 6, 2025 | After close | -$1.24 | -$1.45 | -16.9% | — | -20.80% | -25.13% |
| Aug 7, 2025 | After close | -$1.57 | -$1.10 | +29.9% | — | -8.69% | -14.12% |
| May 6, 2025 | After close | -$1.77 | -$1.68 | +5.1% | — | +14.73% | +20.31% |
| Feb 25, 2025 | After close | -$1.30 | -$1.21 | +6.9% | — | -11.47% | -19.92% |
| Nov 12, 2024 | After close | -$3.32 | -$1.08 | +67.5% | — | +2.50% | -24.08% |
| Aug 8, 2024 | After close | -$3.12 | -$4.40 | -41.0% | — | -5.59% | -1.75% |
| May 9, 2024 | After close | -$3.20 | -$2.87 | +10.3% | — | -17.28% | -6.20% |
| Feb 29, 2024 | After close | -$2.80 | -$2.94 | -5.0% | — | -15.13% | -24.34% |
DNA Earnings FAQ
Answers computed from Ginkgo Bioworks Holdings, Inc.'s reported history
DNA has no upcoming report date in the calendar yet. It last reported on Nov 5, 2026; companies usually report every three months.
Over the last 11 quarters with a usable EPS surprise, DNA beat the consensus estimate 7 times (64%), missed 4 and landed in line 0. 1 quarter where our data sources disagree on beat versus miss are shown but not counted.
Across its last 12 quarters with a measured reaction, DNA moved an average of ±13.6% in the first session after reporting. It closed higher 25% of the time; the largest gain was 14.7% and the largest drop -30.5%.
DNA fell in the first session after 4 of its last 7 EPS beats (57%). A beat that was already priced in, or weaker guidance, can send a stock lower. In 2 of the 4 of those falls where price data is available, the stock had already risen before the report.
Across its last 12 quarters with price data, DNA moved an average of +4.3% in the 20 trading sessions before reporting and was higher in 58% of them. After a run-up of 3% or more (5 quarters), it fell the next day 80% of the time, averaging -8.8%. After a drop of 3% or more (5 quarters), it rose the next day 20% of the time, averaging -8.4%. This describes past reports; it is not a forecast.
In 12 reports DNA opened at least 1% away from the previous close. It gave back half or more of that gap by the close 3 of 12 times (25%), and fully reversed 2 times. A fade means the opening move was partly undone during the first session.
How we calculate these numbers · DNA: 12 reported quarters, latest Nov 5, 2026. Information only, not investment advice.
Looking for more on DNA?
Price charts, forecast, fundamentals and risk pages for DNA are not on Tickzen yet. You can run a full stock analysis now.
Run the DNA Stock AnalyzerLatest TickZen Insights
AbbVie (ABBV) Q3 2026 Earnings Preview: Will Skyrizi and Rinvoq be able to justify the 20x?By Vishal Jadaun
Alphabet (GOOG) Q3 2026 Earnings Preview: Will Cloud Overtake Capex?By Vishal Jadaun
HSBC Q3 2026 Earnings Preview: Is the $46bn NII Guide Too Low?By Vishal Jadaun